SEOUL, South Korea, April 22, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the presentation of seven posters at the American Association for...

Lunit: A new study published in the Journal for ImmunoTherapy of Cancer (JITC) shows that Lunit's AI-powered biomarker "Lunit SCOPE IO" can predict favorable outcomes of Inflamed Immune Phenotype patients treated with Immune Checkpoint...

While it's long been understood that predicting outcomes in patients with cancer requires considering many factors, such as patient history, genes and disease pathology, clinicians struggle with integrating this information to make decisions...

Paige: Company announces CE-IVD and UKCA designations of its new digital biomarker assay, HER2Complete, to identify patients with expression of HER2 in breast cancer The tool has revealed HER2 expression in HER2-negative and HER2-low...

Aiforia announces the CE-IVD mark of its Aiforia® Clinical AI Model for Lung Cancer; PD-L1 for assisting pathologists in the fast and accurate primary diagnosis of lung cancer. This latest AI model expands Aiforia’s portfolio of clinical...

Exclusive: combination of drugs causes tumours to vanish in some terminally ill patients, study finds A new cancer treatment can wipe out tumours in terminally ill head and neck cancer patients, scientists have discovered. In a landmark...